Ropinirole treatment in Parkinson's disease associated with higher serum level of inflammatory biomarker NT-proCNP

Neuroscience Letters

Volumn 566, Issue , 2014, Pages 147-150

  Tomasiuk, Ryszard ^a   Szlufik, Stanislaw ^b   Friedman, Andrzej ^b   Koziorowski, Dariusz ^b  

^a Brodnowski Hospital Warsaw   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Biomarker; CNP; Dopamine agonist; Inflammatory; Parkinson's disease

Indexed keywords

NATRIURETIC PEPTIDE TYPE C; ROPINIROLE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE;

BIOMARKER; CNP; DOPAMINE AGONIST; INFLAMMATORY; PARKINSON'S DISEASE;

ADULT; ANTIPARKINSON AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DOPAMINE AGONISTS; FEMALE; HUMANS; INDOLES; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, C-TYPE; PARKINSON DISEASE;

EID: 84896473473     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.02.053     Document Type: Article

References (19)

1. Teismann P., Tieu K., Cohen O., Choi D.K., Wu D.C., Marks D., Vila M., Jackson-Lewis V., Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 2003, 18:121-129.
2. Dufek M., Hamanová M., Lokaj J., Goldemund D., Rektorová I., Michálková Z., Sheardová K., Rektor I. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:318-320.
3. Koziorowski D., Tomasiuk R., Szlufik S., Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 2012, 60:762-766.
4. Nagatsu T., Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 2005, 11:999-1016.
5. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 1996, 211:13-16.
6. Reale M., Iarlori C., Thomas A., Gambi D., Perfetti B., Di Nicola M., Onofrj M. Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun. 2009, 23:55-63.
7. Andersohn F., Garbe E. Cardiac and non-cardiac fibrotic reactions caused by ergot-and non-ergot-derived dopamine agonists. Mov. Disord. 2009, 24:129-133.
8. Parissis D., Papachristodoulou A., Dimitriadis A. Inflammatory aneurysm of the abdominal aorta in a patient treated with ropinirole. J. Neurol. 2010, 257:1582-1584.
9. Stingo A.J., Clavell A.L., Heublein D.M., Wei C.M., Pittelkow M.R., Burnett J.C. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am. J. Physiol. 1992, 263:HI318-HI321.
10. Bahrami S., Pelinka L., Khadem A., Maitzen S., Hawa G., van Griensven M., Redl H. Circulating NTproCNP predicts sepsis in multiple-traumatized patients without traumatic brain injury. Crit. Care Med. 2010, 38:161-166.
11. Koch A., Voigt S., Sanson E., Dückers H., Horn A., Zimmermann H.W., Trautwein C., Tacke F. Prognostic value of circulating amino-terminal pro-C-type natriuretic peptide in critically ill patients. Crit. Care 2011, 15:R45.
12. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
13. Parrado A.C., Canellada A., Gentile T., Rey-Roldán E.B. Dopamine agonists upregulate IL-6 and IL-8 production in human keratinocytes. Neuroimmunomodulation 2012, 19:359-366.
14. Kawamata J., Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J. Alzheimers Dis. 2011, 24(Suppl. 2):95-109.
15. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
16. Ben-Shaul Y., Bergman H., Soreq H. Identifying subtle interrelated changes in functional gene categories using continuous measures of gene expression. Bioinformatics 2005, 21:1129-1137.
17. BenMoyal-Segal L., Soreq H. Gene-environment interactions in sporadic Parkinson's disease. J. Neurochem. 2006, 97:1740-1755.
18. Soreq L., Ben-Shaul Y., Israel Z., Bergman H., Soreq H. Meta-analysis of genetic and environmental Parkinson's disease models reveals a common role of mitochondrial protection pathways. Neurobiol. Dis. 2012, 45:1018-1030.
19. Benmoyal-Segal L., Vander T., Shifman S., Bryk B., Ebstein R., Marcus E., Stessman J., Darvasi A., Herishanu Y., Friedman A., Soreq H. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J. 2005, 19:452-454.